摘要
最近几年,越来越多的证据妊娠因素在塑造大脑发育中的作用,以及宫内经历影响后期神经退行性疾病包括帕金森(PD)和阿尔茨海默氏病(AD)。九个月的宫内发育和头三年的产后生活在建立决定一生经历的神经元及神经元和神经胶质细胞连接中显的极为关键。在此,对怀孕期起作用的外在的多重因素,包括产妇饮食、营养不良、压力、高血压、产妇糖尿病、胎儿缺氧、早熟、低出生体重、产前感染、胎儿宫内生长受限,母亲或小孩药物服用都进行记录,以及它们调节脑发育的能力导致总神经元和神经胶质负担个体差异进行了讨论。从最近文献的数据表明神经退行性疾病的预防应被定义为一种阻止神经退行性疾病扩散的方法。“两次打击”假说,首先被应用于PD,后又被成功应用于AD及其它神经退行性疾病的病理假说,揭示我们的注意力应放在我们生命的特殊时期:宫内期及围产期。对神经系统的第一次打击出现在生命的早期,在脑中打上了PD或AD的标记,这将制约我们的抵抗力,或者在我们后期的生命增加对于神经退行性疾病的易感性。总的来说,生命早期事件如何作用于后期产生成年神经退行性疾病,例如PD和AD,是一个具有极大吸引力的新的研究焦点。这个假设暗示对于神经退行性疾病的预防研究应当以怀孕期、围产期的早期生命事件为中心,这也为围产期科学家提供了新的挑战:预防神经退行性疾病。
关键词: 帕金森氏(PD)病,阿尔茨海默氏病,神经退行性疾病,胎儿期方案,围产期方案,脑,发展
Current Medicinal Chemistry
Title:Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?
Volume: 21 Issue: 33
Author(s): G. Faa, MA. Marcialis, A. Ravarino, M. Piras, MC. Pintus and V. Fanos
Affiliation:
关键词: 帕金森氏(PD)病,阿尔茨海默氏病,神经退行性疾病,胎儿期方案,围产期方案,脑,发展
摘要: In recent years, evidence is growing on the role played by gestational factors in shaping brain development and on the influence of intrauterine experiences on later development of neurodegenerative diseases including Parkinson’s (PD) and Alzheimer’s disease (AD). The nine months of intrauterine development and the first three years of postnatal life are appearing to be extremely critical for making connections among neurons and among neuronal and glial cells that will shape a lifetime of experience. Here, the multiple epigenetic factors acting during gestation - including maternal diet, malnutrition, stress, hypertension, maternal diabetes, fetal hypoxia, prematurity, low birth weight, prenatal infection, intrauterine growth restriction, drugs administered to the mother or to the baby – are reported, and their ability to modulate brain development, resulting in interindividual variability in the total neuronal and glial burden at birth is discussed. Data from recent literature suggest that prevention of neurodegeneration should be identified as the one method to halt the diffusion of neurodegenerative diseases. The “two hits” hypothesis, first introduced for PD and successfully applied to AD and other neurodegenerative human pathologies, should focus our attention on a peculiar period of our life: the intrauterine and perinatal periods. The first hit to our nervous system occurs early in life, determining a PD or AD imprinting to our brain that will condition our resistance or, alternatively, our susceptibility to develop a neurodegenerative disease later in life. In conclusion, how early life events contribute to late-life development of adult neurodegenerative diseases, including PD and AD, is emerging as a new fascinating research focus. This assumption implies that research on prevention of neurodegenerative diseases should center on events taking place early in life, during gestation and in the perinatal periods, thus presenting a new challenge to perinatologists: the prevention of neurodegenerative human diseases.
Export Options
About this article
Cite this article as:
Faa G., Marcialis MA., Ravarino A., Piras M., Pintus MC. and Fanos V., Fetal Programming of the Human Brain: Is there a Link with Insurgence of Neurodegenerative Disorders in Adulthood?, Current Medicinal Chemistry 2014; 21 (33) . https://dx.doi.org/10.2174/0929867321666140601163658
DOI https://dx.doi.org/10.2174/0929867321666140601163658 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Epidemics of Obesity and Metabolic Disorders: Are Dietary Fats or Sugars Involved?
Current Nutrition & Food Science Gender Specific Aspects of Cell Death in the Cardiovascular System
Current Pharmaceutical Design Influenza and Stroke Risk: A Key Target Not to be Missed?
Infectious Disorders - Drug Targets Genetic Signatures in the Treatment of Stroke
Current Pharmaceutical Design Modulation of Rack-1/PKCβII Signalling By Soluble AβPPα in SH-SY5Y Cells
Current Alzheimer Research Human Immunodeficiency Virus-Mononuclear Phagocyte Interactions:Emerging Avenues of Biomarker Discovery, Modes of Viral Persistence and Disease Pathogenesis
Current HIV Research Targeting Protozoan Parasite Metabolism: Glycolytic Enzymes in the Therapeutic Crosshairs
Current Medicinal Chemistry The Genetic and Epigenetic Effects of 5-Azacytidine and its Major Breakdown Product Guanylurea
Epigenetic Diagnosis & Therapy (Discontinued) Testicular Cell Junction: A Novel Target for Male Contraception
Current Medicinal Chemistry Evidence of Lifestyle Modification in the Management of Hypercholesterolemia
Current Cardiology Reviews Hydrochlorothiazide vs. Chlorthalidone as the Optimal Diuretic for the Management of Hypertension
Current Pharmaceutical Design Good Epidemiologic Practice in Retinitis Pigmentosa: From Phenotyping to Biobanking
Current Genomics Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Can HIV be Cured? Mechanisms of HIV Persistence and Strategies to Combat It
Current HIV Research Application of RNA Interference for the Control of Female Reproductive Functions
Current Pharmaceutical Design Inhibitors of Nitrogen Oxide Species Production in Animal Models of Inflammation and Future Directions for Therapy in Inflammatory Disorders
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Birt-Hogg-Dubé Syndrome, a Genodermatosis that Increases Risk for Renal Carcinoma
Current Molecular Medicine Pharmacogenetically Tailored Treatments for Heart Disease
Current Pharmaceutical Design An Overall Picture of Chemokine Receptors: Basic Research and Drug Development
Current Pharmaceutical Design Future Prospect of RNA Interference for Cancer Therapies
Current Drug Targets